Orthofix’s M6-C artificial disc is being evaluated for contiguous two-level symptomatic cervical radiculopathy, according to an Aug. 2 news release.

Four things to know:

1. The first patient implant was completed by spine surgeon Todd Lanman, MD; 263 patients were enrolled in the study.

2. The FDA is conducting a U.S. Investigational Device Exemption study to compare the M6-C artificial disc and the anterior cervical discectomy and fusion for treating two-level symptomatic cervical radiculopathy.

3. Dr. Lanman said: “The M6-C artificial cervical disc two-level study will provide additional data to validate the effectiveness of disc replacement over fusion in patients suffering from degeneration in two contiguous levels.”

4. Previous long-term studies have shown patients who received the M6-C in an artificial cervical disc single-level clinical trial “continue to have statistically significant benefits at three and four years” compared to anterior cervical discectomy and fusion patients.”


Ready to reclaim your life? Get in touch today.